Prostate Cancer Outcomes Comparable for Transgender Women, Cisgender Men
By Elana Gotkine HealthDay Reporter
FRIDAY, July 26, 2024 -- Most prostate cancer outcomes do not differ significantly between transgender women (TGW) and cisgender (CG) men, including prostate cancer-specific mortality, according to a study published online July 21 in Cancer.
Margaret Meagher, M.D., from the University of California San Diego School of Medicine in La Jolla, and colleagues compared oncological characteristics and survival outcomes between TGW and CG men with prostate cancer using data from the Veterans Affairs Informatics and Computing Infrastructure database (1999 to 2020) and the Surveillance, Epidemiology, and End Results-Medicare database (2010 to 2017). The groups were matched in a 5:1 ratio (CG:TGW) based on age, race, year of diagnosis, and Charlson Comorbidity Index score. Data were included for 1,194 patients: 199 TGW and 995 CG.
The researchers found that there were no significant associations between transgender identity and metastatic presentation, high-risk localized disease, or prostate cancer-specific mortality. There was a significant association seen between transgender identity and improved overall survival.
"In contrast to previous studies, we did not detect worsened prostate cancer outcomes within [the transgender] community," the authors write. "These conflicting data highlight the need for further investigation."
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-27 05:15
Read more
- Prevalence of Diabetes 15.8 Percent in U.S. Adults From 2021 to 2023
- Flu Vaccine Coverage 80.7 Percent for Health Workers in Acute Care Hospitals
- Beta Blockers May Cause Depressive Symptoms
- About 1 in 10 U.S. Adults Have High Cholesterol
- 24.3 Percent of U.S. Adults Had Chronic Pain in Past Three Months in 2023
- Too Many Meds: 'Polypharmacy' Can Really Harm Alzheimer's Patients
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions